Ignite Creation Date:
2025-12-25 @ 1:18 AM
Ignite Modification Date:
2025-12-25 @ 11:26 PM
Study NCT ID:
NCT00334893
Status:
COMPLETED
Last Update Posted:
2017-11-29
First Post:
2006-06-07
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2006-04
Start Date Type:
None
Primary Completion Date:
2012-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-03
Completion Date Type:
ACTUAL
First Submit Date:
2006-06-07
First Submit QC Date:
None
Study First Post Date:
2006-06-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2013-10-16
Results First Submit QC Date:
None
Results First Post Date:
2013-12-10
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-10-24
Last Update Post Date:
2017-11-29
Last Update Post Date Type:
ACTUAL